Discover the latest content that has just been published on Research Tree
Q4/20 operational EBIT of EUR 49m (Arctic: EUR 59m, Cons.: EUR 65m)
NIBD of EUR 1,460m vs EUR 1,459m in Q3/20 and EUR 1.4bn target
Harvesting volumes of 127’t – 1.8’t below expectations
Full Q4/20 report due 17 February
Companies: Mowi ASA
The 2021 volume guidance was disappointing vs our estimate and, coupled with lower price assumptions, we have lowered our estimates in this update. Supply prospects are still healthy and demand could be stronger for longer once the market normalizes. However, we still see high uncertainty short-term and believe consensus will move lower for Q4/20 and H1/21 – we are ~20% below for 2021. We stick to Hold and lower our TP to NOK 170 (175).
EBIT of EUR 80m, in line with the trading update
No dividend for Q3/20 (Arctic: NOK 0, Cons.: NOK 0.13)
Unchanged 2020 volume guidance at 442’t, 2021 at 445’t (new)
Estimates to be revised lower due to recent salmon sales price trend
Q3/20 operational EBIT of EUR 80m (Arctic: EUR 81m, Cons.: EUR 69m)
NIBD of ~ EUR 1,460m – marginally above our EUR 1,443m forecast
Harvesting volumes of 126’t – 2’t below expectations
Q3/20 report due on Wednesday 4 November
We expect Mowi to release its Q3 trading update around 15 October. Following lower (~NOK 1.5/kg) than previously expected salmon prices for the quarter, we now expect an EBIT of EUR 81m (95) but above consensus at EUR 69m. Our estimates are unchanged from Q4 onwards. Current salmon prices in the mid NOK 40s and adverse demand effects from Covid-19 represent short-term risks. We stick to Hold and our NOK 175 target price.
Mowi reported an operational EBIT of EUR 99m – in line with its trading update guiding. The company’s opex/kg is high, and we have lowered our estimates by 6% and 7% for 2020–21. As Mowi’s NIBD is on par with its target, we now assume zero dividends for H2/20, while expect NOK 8 per share for both 2021 and 2022. The company is however vulnerable to soft salmon prices, and we stick to our Hold rating and lower our TP to NOK 175 (185).
EBIT of EUR 99m, in line with trading update guiding of EUR 96m
No dividend for Q2/20 (Arctic: NOK 1.0, Cons.: NOK 0.8)
FY/20 volume guiding lowered by 8’t (Scotland) to 442’t
Estimates to be revised lower by 5-10%
Q2/20 operational EBIT of EUR 96m (Arctic: EUR 80m, Cons.: EUR 81m)
Better than expected margins in all regions except Norway
NIBD at EUR 1,380m vs EUR 1,357m in Q1/20 (Arctic: EUR 1,359m)
Share price relief likely due to earnings beat
Salmon prices held up much better than feared during Q2/20, and although Norwegian prices came in NOK 4/kg above our previous assumptions, US prices disappointed. Mowi is set to release its trading update around 15 July, and we now expect an operational EBIT of EUR 80m (83) vs consensus at EUR 75m. Seasonality adds short-term risk, and we stick to our Hold rating as well as our NOK 185 target price in this preview.
Covid-19 has been identified on a cutting board for salmon
The Chinese have apparently stopped all sales of salmon
China comprises 5% of global demand
Short-term noise and bad timing, but very modest impact longer-term
The Q1/20 report contained few surprises with figures in-line with the trading update. The FY/20 volume guidance was kept unchanged and costs in all regions except for Scotland are expected to be stable going into Q2/20. We have lowered our FY/20 estimates by 10% as we previously expected lower costs, while we have made minor changes to FY/21. We stick to our Hold rating as well as our NOK 185 target price.
EBIT of EUR 109m in line with trading update guiding (EUR 107m)
FY/20 volume guidance reiterated at 450’t (450’t)
FY/20 cash flow guiding virtually unchanged
FY/20 estimates to be lowered by ~10% (costs), modest FY/21 changes
Q1/20 EBIT of EUR 107m (Arctic: 128m, Cons: EUR 155m)
Harvesting volumes of 83’t (84’t)
EBIT/kg margins below expectations in all regions except for Chile
Postpones dividend in light of COVID-19, costs set to increase
Mowi is expected to release its trading update around 14 April, and we expect a Q1 EBIT pre FV adj. of EUR 128m (123) vs consensus at EUR 181m. The Coronavirus has created uncertainty in the entire value chain and spot prices have trended lower recently. We believe there is downside risk to Q2/3 and would not be surprised if Mowi lowers its DPS which would be negative for the yield. We stick to Hold and lower our TP to NOK 190 (235).
We have lowered our 2020 estimates by 8% following higher cost assumptions, mainly for Norway and Canada, as well as a lower contribution from Consumer Products. In addition, higher than expected WC and CapEx implies that Mowi will be above its NIBD target during H2/20, which could represent downside risk to the quarterly DPS of NOK 2.60. As of now, we still find valuation to be fair and stick to our Hold rating and NOK 235 target price.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Mowi ASA.
We currently have 51 research reports from 2
JOHN MENZIES+ (MNZS, BUY at 315p) – Note Publication: Evolutionary trends…
MARKS & SPENCER+ (MKS, HOUSE STOCK at 253p) Q3 TS – FY22 guidance firmed up, c5% underlying upgrade
NORTHBRIDGE INDUSTRIAL SERVICES+ (NBI, House Stock at 174p) - Further progress in Tasman disposal
BUNZL^ (BNZL, BUY at 2723p) – Note published: Solid strategic outlook
TESCO^ (TSCO, BUY at 292p) Q3 & Christmas TS – a beat to expectations and so further FY22 upgrades (c5%)
HILTON FOOD G
Companies: IDEA BRK ASC PFG MAB HFG TSCO BNZL NBI MKS MNZS
Leading proprietary brand British food manufacturer Premier Foods (“Premier”) has issued a very pleasing Q3 FY22 trading statement covering the thirteen weeks (“13W”) to the 1 January 2022.
Companies: Premier Foods plc
Companies: Hotel Chocolat Group Plc
No Joiners Today.
No Leavers Today.
What’s cooking in the IPO kitchen?
Spinnaker Acquisitions plc, intends to join the Main Market (Standard). The Company have conditionally agreed to acquire the entire issued share capital of HomeServe Labs Ltd, a wholly owned subsidiary of FTSE250 quoted public company HomeServe Plc, by way of a reverse takeover conditional, inter alia on relisting and successful completion of fundraising activities to be undertaken by way of a placing and di
Companies: TYM TMG APP BOKU CPP DSG DIS PCIP
What’s cooking in the IPO kitchen?
Genflow Biosciences, a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age intends to float on the Main Market (Standard). The Company will become the first longevity biotechnology firm to list in Europe. Genflow has raised £3.7m in an oversubscribed placing, conditional upon admission becoming effective. The flotation will value Genflow at approximatel
Companies: ZOO AFN ASC CPP FIF PIP
Dekel Agri-Vision has announced strong December 2021 and record full year operational figures which underpin excellent operational and pricing momentum heading into the peak season in January-May 2022. In addition to the recent start-up of the Tiebissou cashew plant, ongoing strength in the core palm oil business should support a re-rating of the stock, especially as operations are continually de-risked and 2022 earnings step up. Reiterate buy.
Companies: Dekel Agri-Vision Plc
Carr’s trading update for the first 20 weeks of FY22 notes that the group has made a positive start to the year with overall performance during the period broadly in line with Board expectations. Importantly, the announcement notes that while the Board sees potential for growth in each of the three divisions, there are limited opportunities to exploit inter-divisional synergies, so it has decided to conduct a strategic review. We leave our estimates unchanged and reiterate our indicative valuati
Companies: Carr's Group PLC
Exactly one year ago, the FTSE 100 closed at 5,862, having fallen 100 points on the day, the lowest point since mid-May 2020, due in part, to the strength of sterling vs US$ at $1.34. One year on, the FTSE 100 has risen to 7,119, a rise of 21%, it remains 7% below the peak in January 2020. From an international viewpoint, US and European markets continue to trade at record highs. The US Federal Reserve is close to withdrawing some of its economic support this year as inflation picks up and the e
Companies: AMYT BAG BVC BRSD CLG CML FBD GDWN INV MACF MNZS MIO NRR NSF NBI MATD PREM QFI RUA SCS STVG SUR SNX UPGS VAST VLS
Wynnstay Group (‘Wynnstay’) has today (30 June 2021) issued a very positive set of interim results for the period ended 30 April 2021. The Group’s balanced business model has come to the fore and delivered record HY pre-tax profits. Trading momentum from H2 FY20A across feed and the Specialist Agriculture Merchanting division has continued in H1 FY21A and has been ahead of management and our expectations. Following the outperformance in feed and Merchanting more than offsetting a weaker arable p
Companies: Wynnstay Group plc
Cake Box’s interim results, covering the 6 months to 30th September 2021, capture a period of strong sales recovery, continued double digit LFL franchise sales growth and accelerated franchisee store openings. Profit growth is a very strong at 122% to CPTP of £3.7m, EPS of 7.5p. An interim DPS of 2.5p is proposed, up 35% yoy. We upgrade our expectations post today’s update, raising FY22 CPTP by c8% to £7.0m and EPS to 14.7p. A net cash position of £7.0m is expected. With the potential for c400 s
Companies: Cake Box Holdings Plc
We were impressed with Diageo’s presentation as it once again demonstrated its ability to outperform the spirits market, which is itself in a strong position to outperform the drinks industry. Buy and hold.
Companies: Diageo plc
We initiate coverage on Goodbody Health Group with a buy rating and 10p price target. Goodbody is a holistic wellness company embarking on an exciting period of growth. It has recently diversified and repositioned its strategy to deepen its clinical offering and take advantage of the long-term structural themes driving customer attitudes to health and wellbeing - which we believe the market is yet to give it value for. With a 40% ROE, Revenue 20A-23E CAGR of 210%, EBITDA 21-23E CAGR of >300% and
Companies: Goodbody Health Inc